CBD oil to reduce the emotional impact of COVID-19 (CBD OIL)
Use of CBD oil to reduce the negative emotional impact of COVID-19: a randomized placebo-controlled clinical trial.
The overall objective of the proposed project is to test the relative clinical efficacy of CBD isolate, full-spectrum CBD oil, broad-spectrum CBD oil, and placebo oil in reducing COVID-induced stress (anxiety, depression, anger, substance use, and sleep disturbance).
The COVID-19 pandemic has hit us like a ton of bricks creating unimaginable levels of unanticipated deaths, financial hardship, and dramatic changes in nearly every facet of our lives, including school, work, shopping, social and family life. Unfortunately, the physical, mental, economic, and health burdens of COVID-19 disproportionately affect the poor, the elderly, and people of color.
The stress induced by these changes, as well as the lack of control we have over them, increases the risk of new mental health problems such as anxiety, depression, substance abuse, sleep disorders, and family violence, as well as exacerbation of symptoms among people with pre-existing psychiatric conditions.
While many people will successfully manage the increased stress caused by COVID-19 on their own or with the support of family and friends, others may need additional help to cope. Consequently, there is an urgent need to develop cost-effective strategies to manage the stress-induced psychological consequences of COVID-19.
There has been considerable excitement in the press about the potential therapeutic use of cannabidiol (CBD) products in the treatment of a variety of physical and mental health problems. Delta-9-tetrahydrocannabinol (delta-9 THC) remains illegal in most states due to its psychoactive abuse potential.
In contrast, cannabidiol (CBD) is not converted to THC in the body and has negligible side effects compared to conventional psychiatric medications (benzodiazepines and antidepressants) commonly prescribed for the treatment of stress-related disorders such as anxiety, depression, and insomnia.
Growing evidence from rodent studies suggests that CBD may confer important and promising health-related benefits, including anti-inflammatory, analgesic, anti-cancer, memory enhancement, and facilitation of fear extinction.
The largest success story of CBD use in humans to date comes from randomized placebo-controlled clinical trials demonstrating a 50% or greater reduction in previously intractable seizures in children suffering from Dravet syndrome and Lennox-Gastaut syndrome.
In addition, several controlled clinical trials have shown promising findings in the reduction of psychotic symptoms among patients with schizophrenia and among young adults presenting with THC-induced psychosis.
Preliminary evidence has begun to emerge that CBD may show promise in the treatment of stress-related disorders. A small pilot trial with 24 patients presenting with social anxiety disorder found that, compared to a placebo, a single 100 mg dose of CBD oil elicited lower levels of anxiety, cognitive impairment, and discomfort in actual speech performance, as well as their anxiety before. speech.
An uncontrolled case series of 11 patients with PTSD who received CBD for 8 weeks reported a 28% reduction in PTSD symptom scores. In a small 4-week placebo-controlled study of 37 Japanese young adults with social anxiety disorder, Masataka found a significant advantage of CBD over placebo in reducing subjects’ scores on two widely used measures of social anxiety symptoms. If you want to learn more, visit site for further information.
Why compare CBD-Isolate to broad-spectrum and full-spectrum CBD? CBD-Isolate is the purest form of CBD. It is made by extracting it from its natural environment, either hemp, which is legal and generally recognized as safe in all states due to its low THC content (less than 0.3%). or the hemp plant which has high levels of THC (up to 30%) and remains a Schedule 1 controlled substance under the Controlled Substances Act of 1970.
